BioControl Medical, Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioControl Medical, Ltd
The top trial reports at the American College of Cardiology's signature annual event will address transcatheter aortic valve replacements, atrial fibrillation ablation, heart-failure neurostimulation treatments, and more.
BioControl Becomes Latest Company To Report Disappointing Outcomes With VNS Therapy For Heart Failure
BioControl Medical has terminated the INOVATE HF trial of its CardioFit vagus nerve stimulator (VNS) for the treatment of heart failure after a pre-specified interim analysis showed the trial had little chance of meeting its primary endpoint. Despite the disappointing results, some physicians remain optimistic about VNS for heart failure and researchers continue to analyze patient subgroups and secondary endpoints to identify potential patients who might benefit from VNS therapy.
At the IATI Biomed conference held in Tel Aviv in May, Medtronic executives hint at an increasing focus on diagnostics, personalized medicine, and patient outcomes.
The cardiology sector, long known as one of the most innovative in medtech, has a new wave of technologies on the horizon that could help reinvigorate the sector and create new multibillion-dollar market opportunities for device manufacturers. We take a closer look at these technologies, which include vagal nerve stimulation, remote monitoring for heart failure, as well as innovation in the percutaneous coronary intervention space, all of which were all in the spotlight at the recent European Society of Cardiology Congress 2014 in Barcelona.
- Implantable Devices